SciSparc GERD acquisition boosts momentum as SPRC enters the device market, aiming to scale globally with innovative endoscopic technology.SciSparc GERD acquisition boosts momentum as SPRC enters the device market, aiming to scale globally with innovative endoscopic technology.

SciSparc Ltd. (SPRC) Stock: Jumps as Company Expands into High-Growth GERD Device Market

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
Scisparc Ltd. (Sprc) Stock: Jumps As Company Expands Into High-Growth Gerd Device Market

SPRC reported a notable stock rise today, with SciSparc trading at $3.0497 as of 10:40 AM EST. The strong increase highlights growing market confidence as SciSparc moves into the expanding GERD device segment. SPRC strengthens its position by advancing its strategy through a new intellectual property acquisition.

SciSparc Ltd. (Nasdaq: SPRC) Stock

SciSparc completed a binding term sheet with Xylo Technologies to obtain patents, trademarks and medical device rights. This action allows SciSparc to pursue commercialization of the MUSE endoscopic system, which supports minimally invasive GERD treatment. SciSparc aims to scale its reach by forming regional distribution agreements across high-growth territories.

The recent stock momentum reflects rising expectations for SciSparc as it diversifies beyond clinical-stage pharmaceutical activity. SPRC looks to build revenue streams through new medical technologies, reinforcing growth ambitions. SciSparc positions itself to capture value in a market expected to expand gradually.

Expansion Through Strategic Technology Acquisition

SPRC  plans to issue ordinary shares representing 19.99% of its capital to Xylo upon closing. The company may also opt to issue pre-funded warrants, providing flexibility during the transaction. The assets obtained include full ownership of the MUSE system and related intellectual property.

SciSparc expects to replicate Xylo’s prior commercialization structure to reach major medical markets. In 2019, Xylo secured $3 million upfront from a China licensing agreement, and SciSparc now seeks similar partnerships abroad. SciSparc targets North America, Europe and Latin America, where demand continues to rise.

The MUSE™ system is designed for transoral fundoplication, enabling GERD symptom relief through a non-surgical method. SciSparc anticipates increased adoption due to growing preference for minimally invasive procedures. This technology aligns with long-term healthcare trends focused on efficiency and patient recovery.

Market Outlook and Industry Context

According to industry research, the global GERD device market reached $2.5 billion in 2024. It is projected to reach $3.03 billion by 2030 at a CAGR of 3.24% from 2025. Consequently, SciSparc aligns with a sector demonstrating stable demand and gradual growth.

SciSparc’s expansion comes amid broader healthcare innovations targeting chronic digestive conditions. The company supports continued development through its majority-owned subsidiary, NeuroThera Labs Inc. This move signals SciSparc’s intent to extend beyond pharmaceuticals into high-value medical equipment.

SciSparc remains subject to completion of definitive agreements before finalizing the acquisition. The company maintains confidence in closing terms without regulatory complications. In the meantime, SciSparc continues advancing toward commercial readiness while capitalizing on current momentum.

Stock Performance and Strategic Position

SciSparc stock stabilized around $3.05 following initial volatility during market open. The trading surge indicates stronger recognition of the company’s new strategic direction. SPRC reinforces long-term positioning through technological expansion and wider geographic outreach.

SciSparc develops pharmaceutical candidates and now broadens ambitions within high-potential medical device markets. Its latest acquisition effort supports diversification and revenue acceleration. SPRC demonstrates proactive steps to strengthen competitiveness and market presence.

SciSparc plans further updates as negotiations progress and commercialization strategies unfold. The company remains focused on execution while maintaining regulatory compliance. SPRC moves forward with momentum as it transitions into the GERD device industry.

This article was originally published as SciSparc Ltd. (SPRC) Stock: Jumps as Company Expands into High-Growth GERD Device Market on Crypto Breaking News – your trusted source for crypto news, Bitcoin news, and blockchain updates.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Is Putnam Global Technology A (PGTAX) a strong mutual fund pick right now?

Is Putnam Global Technology A (PGTAX) a strong mutual fund pick right now?

The post Is Putnam Global Technology A (PGTAX) a strong mutual fund pick right now? appeared on BitcoinEthereumNews.com. On the lookout for a Sector – Tech fund? Starting with Putnam Global Technology A (PGTAX – Free Report) should not be a possibility at this time. PGTAX possesses a Zacks Mutual Fund Rank of 4 (Sell), which is based on various forecasting factors like size, cost, and past performance. Objective We note that PGTAX is a Sector – Tech option, and this area is loaded with many options. Found in a wide number of industries such as semiconductors, software, internet, and networking, tech companies are everywhere. Thus, Sector – Tech mutual funds that invest in technology let investors own a stake in a notoriously volatile sector, but with a much more diversified approach. History of fund/manager Putnam Funds is based in Canton, MA, and is the manager of PGTAX. The Putnam Global Technology A made its debut in January of 2009 and PGTAX has managed to accumulate roughly $650.01 million in assets, as of the most recently available information. The fund is currently managed by Di Yao who has been in charge of the fund since December of 2012. Performance Obviously, what investors are looking for in these funds is strong performance relative to their peers. PGTAX has a 5-year annualized total return of 14.46%, and is in the middle third among its category peers. But if you are looking for a shorter time frame, it is also worth looking at its 3-year annualized total return of 27.02%, which places it in the middle third during this time-frame. It is important to note that the product’s returns may not reflect all its expenses. Any fees not reflected would lower the returns. Total returns do not reflect the fund’s [%] sale charge. If sales charges were included, total returns would have been lower. When looking at a fund’s performance, it…
Share
BitcoinEthereumNews2025/09/18 04:05
Pro Global Scales Latin American Hub as Hybrid Model Accelerates Latin America Growth

Pro Global Scales Latin American Hub as Hybrid Model Accelerates Latin America Growth

Pro Global is accelerating its expansion in Latin America, with investment in its regional head office in Argentina as both international and domestic carriers
Share
ffnews2026/03/23 08:00
Tokenized deposits push Europe toward next-gen digital money

Tokenized deposits push Europe toward next-gen digital money

The post Tokenized deposits push Europe toward next-gen digital money appeared on BitcoinEthereumNews.com. As banks rewire payments and settlement systems, tokenized
Share
BitcoinEthereumNews2026/03/23 18:29